BBP vs. CNCR

Last updated Jun 5, 2026

BBP (Virtus LifeSci Biotech Products ETF) and CNCR (Loncar Cancer Immunotherapy ETF) are both Health & Biotech Equities funds - BBP tracks the LifeSci Biotechnology Products Index while CNCR tracks the Loncar Cancer Immunotherapy Index. Both are passively managed. Both charge a 0.79% expense ratio.

Performance

BBP vs. CNCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Virtus LifeSci Biotech Products ETF (BBP) and Loncar Cancer Immunotherapy ETF (CNCR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

BBP

• 1D: 2.44%
• 1M: -0.92%
• YTD: 8.38%
• 6M: 9.14%
• 1Y: 48.00%
• 3Y*: 17.11%
• 5Y*: 10.90%
• 10Y*: 11.72%

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

BBP vs. CNCR - Yearly Performance Comparison

	2026 (YTD)
BBP Virtus LifeSci Biotech Products ETF	5.61%
CNCR Loncar Cancer Immunotherapy ETF	0.00%

BBP vs. CNCR - Sectors Allocation Comparison

Sectors	BBP	CNCR
Healthcare	100.0%	96.6%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Financial Services	-	3.3%
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

BBP vs. CNCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BBP

BBP Risk / Return Rank: 70
BBP Sharpe Ratio Rank: 61
BBP Sortino Ratio Rank: 62
BBP Omega Ratio Rank: 55
BBP Calmar Ratio Rank: 89
BBP Martin Ratio Rank: 82

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BBP vs. CNCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Virtus LifeSci Biotech Products ETF (BBP) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BBP	CNCR	Difference
Sharpe ratio: Return per unit of total volatility	2.02	—	—
Sortino ratio: Return per unit of downside risk	2.87	—	—
Omega ratio: Gain probability vs. loss probability	1.33	—	—
Calmar ratio: Return relative to maximum drawdown	5.20	—	—
Martin ratio: Return relative to average drawdown	16.27	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	BBP	CNCR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.02	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.42	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.43	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.40	—	—

Drawdowns

BBP vs. CNCR - Drawdown Comparison

The maximum BBP drawdown since its inception was -44.32%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for BBP and CNCR.

Drawdown Indicators

	BBP	CNCR	Difference
Max Drawdown Largest peak-to-trough decline	-44.32%	0.00%	-44.32%
Max Drawdown (1Y) Largest decline over 1 year	-9.28%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-26.09%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-38.28%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-44.32%	—	—
Current Drawdown Current decline from peak	-4.18%	0.00%	-4.18%
Average Drawdown Average peak-to-trough decline	-12.02%	0.00%	-12.02%
Ulcer Index Depth and duration of drawdowns from previous peaks	2.96%	—	—

Volatility

Volatility by Period

	BBP	CNCR	Difference
Volatility (1M) Calculated over the trailing 1-month period	8.03%	—	—
Volatility (6M) Calculated over the trailing 6-month period	18.52%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	23.84%	0.00%	+23.84%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	26.37%	0.00%	+26.37%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	27.41%	0.00%	+27.41%

BBP vs. CNCR - Expense Ratio Comparison

Both BBP and CNCR have an expense ratio of 0.79%.

Dividends

BBP vs. CNCR - Dividend Comparison

Neither BBP nor CNCR has paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BBP Virtus LifeSci Biotech Products ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.18%	0.00%	1.29%
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Which ETF is better, BBP or CNCR?

Both ETFs have the same 0.79% expense ratio. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, BBP or CNCR?

BBP and CNCR have the same expense ratio: 0.79% per year.

Which ETF pays a higher dividend yield, BBP or CNCR?

BBP and CNCR have nearly identical dividend yields, around 0.00%.

What is the main difference between BBP and CNCR?

BBP tracks LifeSci Biotechnology Products Index, while CNCR tracks Loncar Cancer Immunotherapy Index. They also come from different issuers: Virtus Investment Partners and Exchange Traded Concepts.